Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

BioNTech AG. (9/19/17). "Press Release: BioNTech AG to Present at Cantor Fitzgerald Healthcare Conference". Mainz.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation BioNTech AG
  Today BioNTech SE (Nasdaq: BNTX)
  Group BioNTech (Group)
  Organisation 2 Cantor Fitzgerald & Co.
  Group Cantor Fitzgerald (Group)
Products Product Cantor Fitzgerald Healthcare Conference 2017 New York
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index term Index term BioNTech–Cantor Fitzgerald: investor conference, 201709 supply service BioNTech presents at Cantor Fitzegerald Global Healthcare Conference in NY
Persons Person Marett, Sean (BioNTech 202012 CBO + CCO 201506 COO before Evotec)
  Person 2 Jehle, Regina (Abivax 201912– Director of Communications before BioNTech 2014– 2019)

BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the Cantor Fitzgerald Healthcare Conference that is being held in New York, NY from September 25-27, 2017. The presentation is scheduled for Tuesday, September 26 at 2:50 PM Eastern Daylight Time.

Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations and a summary of its most recent Nature publication related to its neo-epitope based individualized mRNA cancer immunotherapeutic.

For more information, please contact:

General Inquiries:

BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273

US Media & Investors:
ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282

International Media & Investor Inquiries:
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for treatment of cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel bispecific antibody- based immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at

Record changed: 2021-04-27


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

» top